A Phase 2 study of EP0057 and Olaparib in ovarian cancer patients

• Research type

  Research Study

• Full title

  A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance

• IRAS ID

  1003422

• Contact name

  Rowan Miller

• Contact email

  rowan.miller1@nhs.net

• Eudract number

  2020-003083-98

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  20/LO/1129

• Date of REC Opinion

  16 Dec 2020

• REC opinion

  Further Information Favourable Opinion